Ann Dermatol.  2018 Apr;30(2):150-157. 10.5021/ad.2018.30.2.150.

Can the Cytokine Analysis of the Scales on Alopecic Patch Predict the Response to Diphenylcyclopropenone Treatment in Alopecia Areata Patients?

• Lee SH
• Moon JH
• Ban DH
• Byun JW
• Shin J
• Choi GS

• KMID: 2414675
• DOI: http://doi.org/10.5021/ad.2018.30.2.150

Abstract

BACKGROUND
Contact immune modulating therapy with diphenylcyclopropenone (DPCP) is a topical treatment option for extensive alopecia areata (AA). Because the response to DPCP treatment varies according to the patient, and it takes several months to evaluate the clinical effectiveness of the treatment, it is necessary to identify the factors that can predict the prognosis of the disease while treating with topical DPCP.
OBJECTIVE
In this study, cytokine levels in the scales of alopecic patches were investigated to identify whether they could predict response to DPCP during the early treatment period.
METHODS
Scale samples were taken from the alopecic patches in eight AA patients at 1 week, 2 months, and 4 months after DPCP sensitization. The patients were divided into responders and non-responders according to the clinical responses of DPCP treatment. Interferon (IFN)-gamma, interleukin (IL)-2, IL-12 and IL-10 levels of the subjects were compared in several perspectives.
RESULTS
Cytokine levels after 1 week of DPCP sensitization showed no statistically significant difference between two groups. After 4 months of treatment, IFN-gamma levels were significantly lower in responders than in non-responders.
CONCLUSION
The results of this study show IFN-gamma levels in the scales of alopecic patches might possibly reflect the clinical response in AA patients treated with DPCP. However, initial cytokine levels could not predict the treatment response.

Keyword

Alopecia areata; Cytokines; Diphenylcyclopropenone

MeSH Terms

Alopecia Areata*
Alopecia*
Cytokines
Humans
Interferons
Interleukin-10
Interleukin-12
Interleukins
Prognosis
Treatment Outcome
Weights and Measures*
Cytokines
Interferons
Interleukin-10
Interleukin-12
Interleukins

Figure

• 

  Fig. 1 Gross photograph of patient no. 3 (responder) and patient no. 7 (non-responder) at before and 4 months after DPCP treatment. Before treatment (A, E: patient no. 3; C, G: patient no. 7). After 4 months of treatment (B, F: patient no. 3; D, H: patient no. 7).

• 

  Fig. 2 Dot plot showing each value of cytokines in the patients treated with diphenylcyclopropenone (DPCP). Red bar in the graph indicates mean values. Before significant clinical differences appear (1 week and 2 months after treatment), interferon (IFN)-gamma, interleukin (IL)-12, and IL-10 showed no significant difference between responders and non-responders. IL-2 levels at 1 week showed difference between the two groups, however, it did not showed difference at 4 months after treatment. IFN-gamma levels at 4 months after DPCP treatment showed statistically significant differences between responder and non-responder groups (p=0.024).

Reference

1. Gregoriou S, Papafragkaki D, Kontochristopoulos G, Rallis E, Kalogeromitros D, Rigopoulos D. Cytokines and other mediators in alopecia areata. Mediators Inflamm. 2010; 2010:928030. PMID: 20300578.

2. Park J, Yoo KH, Rho YK, Han TY, Li K, Seo SJ, et al. Comparison of therapeutic effect of high dose corticosteroid pulse therapy and combination therapy of cyclosporine with low does corticosteroid for severe alopecia areata. Korean J Dermatol. 2009; 47:1220–1226.

3. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol. 1987; 123:1491–1493. PMID: 3314718.

4. Mitchell AJ, Douglass MC. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol. 1985; 12:644–649. PMID: 3989026.

5. Berth-Jones J, Mc Burney A, Hutchinson PE. Diphencyprone is not detectable in serum or urine following topical application. Acta Derm Venereol. 1994; 74:312–313. PMID: 7976097.

6. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998; 39:751–761. PMID: 9810892.

7. Higgins E, du Vivier A. Topical immunotherapy: unapproved uses, dosages, or indications. Clin Dermatol. 2002; 20:515–521. PMID: 12435522.

8. Ohlmeier MC, Traupe H, Luger TA, Böhm M. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata-a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol. 2012; 26:503–507. PMID: 21569118.

9. Barahmani N, Lopez A, Babu D, Hernandez M, Donley SE, Duvic M. Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. Clin Exp Dermatol. 2010; 35:409–416. PMID: 19874320.

10. Tembhre MK, Sharma VK. T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol. 2013; 169:543–548. PMID: 23607748.

11. Ito T, Tokura Y. The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata. Exp Dermatol. 2014; 23:787–791. PMID: 25040075.

12. Zöller M, McElwee KJ, Vitacolonna M, Hoffmann R. The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood mononuclear cells. Exp Dermatol. 2004; 13:435–444. PMID: 15217364.

13. Dreher F, Modjtahedi BS, Modjtahedi SP, Maibach HI. Quantification of stratum corneum removal by adhesive tape stripping by total protein assay in 96-well microplates. Skin Res Technol. 2005; 11:97–101. PMID: 15807806.

14. Hendrix SW, Miller KH, Youket TE, Adam R, O'Connor RJ, Morel JG, et al. Optimization of the skin multiple analyte profile bioanalytical method for determination of skin biomarkers from D-Squame tape samples. Skin Res Technol. 2007; 13:330–342. PMID: 17610656.

15. De Jongh CM, Verberk MM, Withagen CE, Jacobs JJ, Rustemeyer T, Kezic S. Stratum corneum cytokines and skin irritation response to sodium lauryl sulfate. Contact Dermatitis. 2006; 54:325–333. PMID: 16787454.

16. de Jongh CM, Verberk MM, Spiekstra SW, Gibbs S, Kezic S. Cytokines at different stratum corneum levels in normal and sodium lauryl sulphate-irritated skin. Skin Res Technol. 2007; 13:390–398. PMID: 17908190.

17. Voegeli R, Rawlings AV, Breternitz M, Doppler S, Schreier T, Fluhr JW. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol. 2009; 161:70–77. PMID: 19416247.

18. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines--part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004; 51:440–447. PMID: 15337988.

19. Olsen EA, Canfield D. SALT II: a new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016; 75:1268–1270. PMID: 27846957.

20. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. J Am Acad Dermatol. 2010; 62:191–202. PMID: 20115946.

21. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res. 1980; 267:109–114. PMID: 6446265.

22. Herbst V, Zöller M, Kissling S, Wenzel E, Stutz N, Freyschmidt-Paul P. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol. 2006; 16:537–542. PMID: 17101475.

23. Hoffmann R, Wenzel E, Huth A, van der Steen P, Schäufele M, Henninger HP, et al. Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol. 1994; 103:530–533. PMID: 7930677.

24. Teraki Y, Imanishi K, Shiohara T. Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Acta Derm Venereol. 1996; 76:421–423. PMID: 8982401.

25. Freyschmidt-Paul P, McElwee KJ, Happle R, Kissling S, Wenzel E, Sundberg JP, et al. Interleukin-10-deficient mice are less susceptible to the induction of alopecia areata. J Invest Dermatol. 2002; 119:980–982. PMID: 12406350.

26. Park J, Lee KH, Kim JW, Ro YS, Park CW, Park WS, et al. The therapeutic efficacy of the moisturizer APDDR-0801 for patients with atopic dermatitis. Korean J Dermatol. 2010; 48:93–100.